Balstilimab is an investigational intravenous immunotherapy. It inhibits the activity of programmed death-1 (PD-1), an immune checkpoint protein that helps restrain the immune system. Balstilimab is proposed for the second-line treatment of advanced cervical cancer in patients with disease progression or who experience a relapse during or after chemotherapy.

If you have a Hayes login, click here to view the full report on the Knowledge Center.